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SUMMARY
Smith-Magenis syndrome (SMS) is a rare genetic
neurodevelopmental disorder characterised by
behavioural disturbances, intellectual disability and early
onset obesity. The physical features of this syndrome are
well characterised; however, behavioural features, such
as sleep disturbance, are less well understood and
difﬁcult to manage. Sleep issues in SMS are likely due to
a combination of disturbed melatonin cycle, facial
anatomy and obesity-related ventilatory problems. Sleep
disorders can be very distressing to patients and their
families, as exempliﬁed by our patient’s experience, and
can worsen behavioural issues as well as general health.
This case demonstrates the successful use of non-
invasive ventilation in treating underlying obesity
hypoventilation syndrome and obstructive sleep apnoea.
As a consequence of addressing abnormalities in sleep
patterns, some behavioural problems improved.
BACKGROUND
Smith-Magenis syndrome (SMS) is a rare neurode-
velopmental disorder caused by a microdeletion of
chromosome 17p11.2, which occurs de novo in
virtually all cases.1–3 The estimated prevalence is
between 1 in 15 000 and 1 in 25 000 live births.2
It was ﬁrst described in 1982, since then the clinical
phenotype has been well described and clear asso-
ciations have been made with sleep disturbances,
intellectual disability and early onset obesity. In
addition, patients display a wide range of behav-
ioural abnormalities, including self-injury, aggres-
sion, tantrums and attention deﬁcits.4 5 Figure 1
summarises common features of the syndrome.
Sleep disorder in SMS can be very distressing to
patients and their families (see ‘patient’s experi-
ence’), and may also be responsible for some behav-
ioural problems.4 5 Many studies have found that
patients with SMS have disturbed circadian
rhythms in melatonin and have hypothesised that
this is the likely cause of sleep disturbance.6
However, melatonin replacement therapy is often
ineffective as treatment. These patients also have a
combination of anatomical features which may lead
to disordered sleep: obesity is common and can be
severe, and SMS facies are characterised by ﬂatten-
ing of the middle of the face and the bridge of the
nose (ﬁgure 2).
CASE PRESENTATION
A 23-year-old man with known SMS attended
respiratory clinic due to his deteriorating breath-
lessness. He had the typical facial appearance asso-
ciated with SMS. In addition, the family reported a
history of excessive eating, behavioural problems
and learning difﬁculties.
Pharmacological treatment included melatonin.
However, his family reported that this treatment
was not effective in normalising his sleep pattern.
His mother described a lifelong history of noisy
breathing with snoring from infancy. The patient
had been investigated extensively and been found to
have narrow nasal airway passages, which led to sur-
gical repair of a deviated septum during childhood.
Unfortunately, this did not improve his symptoms.
There was also a history of excessive daytime
sleepiness with an Epworth score of 23. He slept
upright in a chair, reporting a long sleep latency of
about 1 hour and woke up intermittently with
choking episodes. Consequently, he took frequent
naps during the day. After extensive investigations,
he was diagnosed with obesity hypoventilation syn-
drome (OHS) and obstructive sleep apnoea (OSA).
Periods of worse sleep associated with exacerba-
tions of his behavioural issues. Main problems
reported by his parents included ‘temper tantrums’
where he would become very aggressive, displaying
challenging and attention seeking behaviours on a
daily basis. They also reported a lack of concentra-
tion and difﬁculty ﬁnishing tasks; both of which
were often associated with frustration and distress.
In his social history, he lived with his family and
was dependent on his mother for his care needs.
There were no other family members with relevant
medical conditions.
On examination, he was clinically obese with a body
mass index of 41. Auscultation of his chest revealed
generally good air entry but quiet breath sounds
throughout the lung ﬁelds with no added sounds. The
heart sounds were quiet with no murmurs. Blood pres-
sure was 132/84 mmHg. His jugular venous pressure
was not noticeably elevated, but there was bilateral
pitting oedema up to his thighs. His throat appeared
crowded with a Mallampati score of 4.
INVESTIGATIONS
Preintervention
An inpatient sleep study (polysomnography) was
performed for a duration of just over 6 hours.
Although the study was compromised by a few loss
of signal for oxygen saturation, it was nevertheless
deemed valid for analysis. The study reported 24
obstructive events per hour (/hour) with no central
events. Apnoeas (average duration 18 s) occurred at
24/hour and hypopnoea (average 27 s) occurred at
10/hour, giving an apnoea–hypopnea index (AHI)
of 34/hour, which is suggestive of severe OSA. The
respiratory disturbance index (RDI) was 71/hour.
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There was no evidence of Cheyne-Stokes breathing. There were
55/hour desaturations <90%, although this was limited by some
signal loss. The average heart rate was 92 bpm. Total leg move-
ment occurred at 16/hour with the periodic leg movement
index of 2.3/hour. The snore index was 492/hour. In summary,
these ﬁndings suggest severe OSA.
Spirometry showed a restrictive pattern with forced expira-
tory volume (FEV1) of 53% predicted, forced vital capacity
(FVC) of 58% predicted and FEV1/FVC ratio of 77%. The peak
ﬂow was 61% predicted.
ECG showed sinus rhythm with signs of right-axis deviation
and right ventricular strain. This was consistent with
cardiopulmonary MRI ﬁndings, which demonstrated signiﬁcant
right ventricular hypertrophy. All chamber sizes were normal
and biventricular function was preserved.
Echocardiography was difﬁcult, given his obesity. Right ven-
tricular outﬂow tract velocity time integral was 13 cm and tri-
cuspid regurgitation velocity was 3.3 m/s. Right ventricular
systolic velocity was 10 cm/s. Pulmonary vascular resistance was
calculated at 2.7 Wood units. Findings were consistent with ele-
vation in pulmonary artery pressure. Left ventricle was not
dilated and had good systolic function.
Early morning arterial blood gas (ABG) on room air showed:
pH 7.32, pCO2 9.0 kPa, pO2 7.1 kPa, HCO3 28.0 mmol/L.
Figure 1 Key behavioural features of Smith-Magenis syndrome. Reproduced with permission from the Smith-Magenis Research Foundation.
Figure 2 An adult woman and
young girl with typical facial features
of Smith-Magenis syndrome. Photo
kindly provided by the Smith-Magenis
Foundation UK.
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Postintervention
Early morning ABG on:
Continuous positive airway pressure (CPAP) with pressure of
11 cm H2O: pH 7.33, pCO2 8.6 kPa, pO2 6.7 kPa, HCO3
27.8 mmol/L.
Non-invasive ventilation (NIV) 20/10 cm H2O on room air:
pH 7.34, pCO2 8.1 kPa, pO2 8.1 kPa, HCO3 27.5 mmol/L.
NIV 24/10 cm H2O on room air: pH 7.35, pCO2 7.7 kPa,
pO2 7.7 kPa, HCO3 26.9 mmol/L.
Overnight oxygen monitoring showed mean oxygen satura-
tions of 92.3% with a median of 92.9%. The patient spent
37 min below 90% oxygen saturations during the 5 hour
45 min tracing, with some dipping at the 4% level at the rate of
17/hour. Trace was limited by artefact and the oxygen satura-
tions probe being off the patient’s ﬁnger for much of the night.
TREATMENT
Initial treatment included weight management. In addition to
treating his OSA, he was initially given a trial of CPAP which
improved baseline oxygen saturations and led to some improve-
ment in his symptoms. However, early morning ABG results
showed raised carbon dioxide levels.
As a result of this, he was switched to nocturnal NIV which
was increased to 24 cm H2O inspiratory positive airway pressure
and 10 cm H2O expiratory positive airway pressure, which the
patient tolerated well. This improved the patients ABGs: pH
increased from 7.33 to 7.35 and SpO2 increased from 6.7 to
7.7 kPa.
Supplemental oxygen was not given as the overnight oximetry
on NIV was inconclusive due to signiﬁcant artefact. After discus-
sion with the patient’s family, a decision was reached not to
attempt a further overnight oximetry, given his signiﬁcant symp-
tomatic improvement.
OUTCOME AND FOLLOW-UP
After the initial trial of CPAP, the patient and his family noticed
reduced snoring and nocturnal choking, they also reported an
improvement in the patient’s daytime sleepiness.
Signiﬁcant improvement was noted after switching to noctur-
nal NIV, the nasal mask was tolerated well; the patient used it
each night with no oxygen entrained. The patient reported
much better sleep quality, control of snoring and was much less
sleepy during the day. He also reported improvement of his noc-
turia and peripheral oedema. Repeat overnight oximetry
showed an improvement in mean oxygen saturations and less
reported dips.
The family reported that in addition to a better sleeping
pattern, they had also noticed a signiﬁcant improvement in his
overall quality of life. He appeared to be less agitated and dis-
tressed throughout the day, and there were less frequent temper
tantrum episodes. They felt that the reduction in daytime drow-
siness seemed to improve his concentration and attention span
which had generally improved his overall behaviour.
With assistance from a weight management programme, he
was able to lose 6 kg in 1 year.
DISCUSSION
Sleep disorders are commonly reported in patients with SMS,
the majority of research evidence attributes this to an inverted
diurnal secretion of melatonin.7 8 Several pharmacological treat-
ments have been trialled, including melatonin replacement,
β-agonists and growth hormone replacement. However, the con-
sensus is that if these do not improve sleep disturbance, then the
underlying cause is genetically determined and therefore resist-
ant to interventions.8
However, in some patients with a combination of otolaryngo-
logical abnormalities due to characteristic facial features, obesity
and general hypotonia, there may be a treatable component.
Investigations into respiratory patterns, including full sleep
studies or overnight oxygen oximetry, are rarely discussed but
are important to assess if there is a treatable component to sleep
disturbance. A case report in 2010 supported this; Leoni et al7
described a paediatric patient with SMS who presented with
repeated oxygen desaturations during rapid eye movement
(REM) sleep but with no apnoeas or hypopneas. They suggest
that this could be associated with a subclinical restrictive respira-
tory impairment or an impairment of central respiratory control
during REM sleep and advise recording of respiratory para-
meters in all patients with SMS who complain of sleep
disturbance.7
More recently, Takenouchi et al8 described a patient with
SMS who had signiﬁcant sleep disturbance (frequent nocturnal
awakenings and early awakenings), daytime somnolence and
snoring since infancy which interfered with daytime activities.
The team carried out an overnight polysomnography which
showed severe sleep apnoea (AHI 97.5/hour).8 CPAP was
started which signiﬁcantly improved his daytime somnolence,
snoring and nocturnal wakening, leading to better communica-
tion skills and improved concentration throughout the day.8
In conclusion, disordered sleep in SMS is likely multifactorial.
Obesity-related ventilatory disorders should be considered,
assessed and managed. NIV may dramatically improve sleep and
help with behavioural issues. Further case series are needed to
support the screening of sleep-disordered breathing in SMS.
Patient’s perspective
▸ [He] had breathing problems since birth […] especially at
night and would cough, choke, vomit, waking up at least
4–6 times a night. We all suffered constant sleep
deprivation as he would get up and disturb his siblings.
I would ﬁnd him asleep on the ﬂoor and the stairs.
He would fall asleep throughout the day on his school desk,
going up the stairs, behind the bathroom door. His temper
tantrums were frequent even as a toddler; he would bang
his head on the ﬂoor or the wall, rip up his books
screaming. As he got older the tantrum became more
violent. As he approached his 20s his health issues
escalated. He was ﬂooding the bed three times every night.
His snoring and choking worsened, he simply could not
sleep […] he was exhausted, falling asleep through the day,
snoring very loud, with pitting oedema up to his knees.
▸ From the ﬁrst night [he] had BiPAP his health improved.
I could put him to bed knowing that within 2 min he would
be asleep and be warm and dry. His daytime napping has
improved and he can be more engaged during the day. The
BiPAP has improved his health and life immeasurably. He
feels a lot healthier and is […] losing weight. I feel strongly
that [BiPAP] should be offered to people with Smith-
Magenis. I have always thought [his] breathing problems
were anatomical with his very small nasal passages his
ﬂattened bridge of nose.
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Learning points
▸ Obesity-related ventilatoy disorders should be considered
and investigated in patients with Smith-Magenis syndrome if
they report daytime sleepiness and breathlessness.
▸ Treating obstructive sleep apnoea/obesity hypoventilation
syndrome with nocturnal NIV can improve breathing during
sleep and in turn can reduce daytime sleepiness.
▸ Improving sleep may also help behavioural problems,
concentration and general daytime performance.
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